|
GO_0060139
|
GO_0060139 |
|
|
maternal process involved in parturition
|
GO_0060137 |
[A reproductive process occurring in the mother that results in birth.] |
|
regulation of tube length, open tracheal system
|
GO_0035159 |
[Ensuring that a tube in an open tracheal system is of the correct length.] |
|
fetal process involved in parturition
|
GO_0060138 |
[A reproductive process occurring in the embryo that results in birth.] |
|
positive regulation of antibody-dependent cellular cytotoxicity
|
GO_0001815 |
[Any process that activates or increases the frequency, rate or extent of antibody-dependent cellular cytotoxicity.] |
|
regulation of antibody-dependent cellular cytotoxicity
|
GO_0001813 |
[Any process that modulates the frequency, rate, or extent of antibody-dependent cellular cytotoxicity.] |
|
FYXD domain binding
|
GO_0098750 |
[Binding to a FXYD domain.] |
|
negative regulation of antibody-dependent cellular cytotoxicity
|
GO_0001814 |
[Any process that stops, prevents, or reduces the rate of antibody-dependent cellular cytotoxicity.] |
|
bone cell development
|
GO_0098751 |
[The process whose specific outcome is the progression of a bone cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.] |
|
terminal cell fate specification, open tracheal system
|
GO_0035154 |
[The process in which a cell in an open tracheal system becomes capable of differentiating autonomously into a terminal cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed. Terminal cells send long and bifurcated hollow branches toward target tissues to allow oxygen exchange.] |
|
negative regulation of type I hypersensitivity
|
GO_0001811 |
[Any process that stops, prevents, or reduces the rate of type I hypersensitivity, a type of inflammatory response.] |
|
regulation of type I hypersensitivity
|
GO_0001810 |
[Any process that modulates the frequency, rate, or extent of type I hypersensitivity, a type of inflammatory response.] |
|
negative regulation of hypersensitivity
|
GO_0002884 |
[Any process that stops, prevents, or reduces the frequency, rate, or extent of hypersensitivity.] |
|
obsolete integral component of the cytoplasmic side of the plasma membrane
|
GO_0098752 |
[OBSOLETE. The component of the plasma membrane consisting of the gene products that penetrate only the cytoplasmic side of the membrane.] |
|
positive regulation of type I hypersensitivity
|
GO_0001812 |
[Any process that activates or increases the frequency, rate or extent of type I hypersensitivity, a type of inflammatory response.] |
|
positive regulation of hypersensitivity
|
GO_0002885 |
[Any process that activates or increases the frequency, rate, or extent of hypersensitivity.] |
|
obsolete anchored component of the cytoplasmic side of the plasma membrane
|
GO_0098753 |
[OBSOLETE. The component of the plasma membrane consisting of gene products and protein complexes with covalently attached hydrophobic anchors products that penetrate only the cytoplasmic side of the membrane.] |
|
regulation of hypersensitivity
|
GO_0002883 |
[Any process that modulates the frequency, rate, or extent of hypersensitivity.] |
|
maintenance of seed dormancy by absisic acid
|
GO_0098755 |
[The process by which seed dormancy is maintained by the presence of absisic acid.] |
|
response to interleukin-21
|
GO_0098756 |
[Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-21 stimulus.] |